Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers

Current Topics in Medicinal Chemistry

Volumn 7, Issue 3, 2007, Pages 311-340

  Khanapure, Subhash P ^a,b   Garvey, David S ^a   Janero, David R ^a   Letts, L Gordon ^a  

^a NitroMed Inc   (United States)

^b CreaGen Biosciences Inc   (United States)

Author keywords

Arachidonic acid metabolism; Eosinophils; Fever; Inflammation; Leukotriene B4 receptors; Lipoxin; Lung diseases; Ysteinyl leukotrienes receptors

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [1 (4 CHLOROBENZYL) 5 FLUORO 3 METHYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 7 [3 (3 HYDROXY 4 PHENYL 1 PENTEN 1 YL) 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [4 (2 HYDROXYPHENYL) 2,2 DIMETHYL 1,3 DIOXAN 5 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; ICOSANOID; ILOPROST; INDOMETACIN; LUMIRACOXIB; MONTELUKAST; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PRANLUKAST; ROFECOXIB; UNINDEXED DRUG; VALDECOXIB; ZAFIRLUKAST; ZILEUTON;

ARTHRITIS; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CATALYSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME METABOLISM; ENZYME STRUCTURE; EOSINOPHIL; EPIDERMIS HYPERPLASIA; EYE INFLAMMATION; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HUMAN; ICOSANOID METABOLISM; INFLAMMATORY DISEASE; KIDNEY DISEASE; LIPOGENESIS; LOW DRUG DOSE; LUNG DISEASE; MONOTHERAPY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2 INHIBITORS; EICOSANOIDS; HUMANS; INFLAMMATION; LIPOXYGENASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 33847638020     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779941314     Document Type: Review

References (336)

1. Curtius-Prior, P. The Eicosanoids. London: John Wiely & Sons, Ltd, 2004.
2. Khanapure, S. P.; Letts, L. G. Perspectives and clinical significance of the biochemical and molecular pharmacology of eicosanoids. In: Curtis-Prior P. B.; editor. The Eicosanoids. London: John Wiely & Sons, 2004:131-162.
3. Willis, A. L. CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids, Vol. 1, Part A. Boca Raton: CRC Press, 1987.
4. Willis A. L. CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids, Vol. 1, Part B. Boca Raton: CRC Press, 1987.
5. Whittle, B.; Moncada, S.; Vane, J. Formation of prostacyclin by the gastric mucosa and its action on gastric function. Prostaglandins 1978, 15, 704-705.
6. 2 and prostacyclin. Pharmacol. Rev. 1978, 30, 293.
7. Vane, J. R.; Botting, R. M. Therapeutic roles of selective COX-2 inhibitors. London, UK: William Harvey Press, 2001:1-548.
8. Ford-Hutchinson, A. W.; Bray, M. A.; Shipley, M. E.; Doig, M.; Smith, M. J. H. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980, 286, 264-265.
9. Rokach, J. Leukotrienes and Lipoxygenases, Chemical, Biological and Clinical Aspects. Amsterdam, The Netherlands: Elsevier Science, 1989: 1-518.
10. O'Flaherty, J. T.; Cordes, J.; Redman, J.; Thomas, M. J. 5-Oxo-eicosatetraenoate, a potent human neutrophil stimulus. Biochem. Biophys. Res. Commun. 1993, 192, 129-134.
11. 4 receptor. J. Biol. Chem. 1993, 268, 9280-9286.
12. O'Flaherty, J. T.; Kuroki, M.; Nixon, A. B.; Wijkander, J.; Yee, E.; Lee, S. L.; Smitherman, P. K.; Wykle, R. L.; Daniel, L. W. 5-Oxoeicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway. J. Biol. Chem. 1996, 271, 17821-17828.
13. Rokach, J.; Khanapure, S. P.; Hwang, S. W.; Adiyaman, M.; Lawson, J. A.; FitzGerald, G. A. The isoprostanes: A perspective. Prostaglandins 1997, 54, 823-851.
14. Rokach, J.; Khanapure, S. P.; Hwang, S. W.; Adiyaman, M.; Schio, L.; FitzGerald, G. Isoprostanes, a new class of natural products: synthesis and biosynthesis. Synthesis 1998, 569-580.
15. Hamberg, M.; Samuelsson, B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA 1973, 70, 899-903.
16. Nugteren, D. H.; Hazelhof, E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim. Biophys. Acta 1973, 236, 448-461.
17. Moncada, S.; Gryglewski, R. J.; Bunting, S.; Vane, J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1971, 231, 663-665.
18. 2 biosynthesis. J. Biol. Chem. 1989, 264, 141-150.
19. Smith, C. J.; Zhang, Y.; Koboldt, C. M.; Muhammad, J.; Zweifel, B. S.; Shaffer, A.; Talley, J. J.; Masferrer, J. L.; Seibert, K.; Isakson, P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA 1998, 95, 13313-13318.
20. 2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 2000, 275, 32783-32792.
21. Jakobsson, P.-J.; Thoren, S.; Morgenstren, R.; Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 1999, 96, 7220-7225.
22. Breder, C. D. Perpesctives and clinical significance of arachidonic acid release, action and metabolism in the nervous system. In: Curtis-Prior P.; editor. The Eicosanoids. London: John Wiely & Sons, 2004:447-462.
23. Kojima, F.; Naraba, H.; Sasaki, Y.; Okamato, R.; Koshino, T.; Kawai, S. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J. Rheumatol. 2002, 29, 1836-1842.
24. Feldberg, W.; Kellaway, C. H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J. Physiol. 1938, 94, 187-197.
25. Kellaway, C. H.; Trethewie, E. R. The liberation of slow reacting smooth muscle-stimulating substance in anaphylaxis. Q. J. Exp. Physiol. 1940, 38, 121-145.
26. Murphy, R. C.; Hammarstrom, S.; Samuelsson, B. Leukotriene, C: A slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA 1979, 76, 4275-4279.
27. Yamamoto, S.; Suzuki, H.; Ueda, N.; Takahashi, Y.; Yoshimoto, T. Mammalian Lipoxygenases. In: Curtis-Prior P.; editor. The Eicosanoids. London: John Wiely & Sons, Ltd, 2004:53-59.
28. Fitzsimmons, B. J.; Adams, J.; Evans, J. F.; Leblanc, Y.; Rokach, J. The lipoxins: stereochemical identification and determination of their biosynthesis. J. Biol. Chem. 1985, 260, 13008-13012.
29. Wainwright, S. L.; Powell, W. S. Mechanism for the formation of dihydro metabolites of 12-hydroxyeicosanoids. J. Biol. Chem. 1991, 266, 20899-20906.
30. Khanapure, S. P.; Saha, G.; Powell, W. S.; Rokach, J. The design and synthesis of a 5-HETE affinity chromatography ligand for 5-hydroxyeicosanoid dehydrogenase. Tetrahedron Lett. 2000, 41, 5807-5811.
31. Powell, W. S.; Gravelle, F.; Gravel, S. Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes. J. Biol. Chem. 1992, 267, 19233-19241.
32. 4, a key biochemical intermediate. J. Org. Chem. 1997, 62, 325-330.
33. 4 metabolites. Tetrahedron Lett. 2002, 43, 6063-6066.
34. 4. J. Biol. Chem. 1989, 264, 19469-19472.
35. Lewis, R. A.; Austen, K. F.; Soberman, R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. N. Engl. J. Med. 1990, 323, 645-655.
36. 4. Eur. J. Biochem. 1991, 196, 395-400.
37. Serhan, C. N. Compounds of the arachdonic acid signalling cascade: A brief update and hypothesis. Adv. Rheumatol. Inflammation 1991, 1, 147-149.
38. Fradin, A.; Zirroli, J. A.; Maclouf, J.; Vausbinder, L.; Henson, P. M.; Murphy, R. C. Platelet-activating factor and leukotriene biosynthesis in whole blood. J. Immunol. 1989, 143, 3680-3685.
39. 4: comparision of cells from asthmatic subjects and healthy donors. Ann. Allergy 1990, 64, 287-292.
40. Schauer, U.; Eckhart, A.; Muller, R.; Gemsa, D.; Rieger, C. H. Enhanced leukotriene C4 production by peripheral eosiniphils. Int. Arch. Allergy Appl. Immunol. 1989, 90, 201-206.
41. Woods, J. W.; Coffey, M. J.; Brock, T. G.; P-G. M. Singer, 1. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest. 1995, 95, 2035-2046.
42. Rouzer, C. A.; Kargman, S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J. Biol. Chem. 1988, 263, 10980-10988.
43. Gillard, J.; Ford-Hutchinson, A. W.; Chan, C.; Charleson, S.; Denis, D.; Foster, A.; Fortin, R.; Leger, S.; McFarlane, C. S.; Morton, H.; Piechuta, H.; Riendeau, D.; Rouzer, C. A.; Rokach, J.; Young, R.; MacIntyre, D. E.; Peterson, L.; Bach, T.; Eiermann, G.; Hoplle, S.; Hupe, J.; Luell, S.; Metzger, J.; Meurer, R.; Miller, D.; Opas, E.; Pacholok, S. L-663, 536 (MK-886) (3-[1-(4-chlorobenzyl)-3t-butyl-thio-5-isopropylindol-2-yl]-2, 2-dimethyl-propanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. & Pharmacol. 1989, 67, 456-464.
44. Rouzer, C. A.; Ford-Hutchinson, A. W.; Morton, H. E.; Gillard, J. W. MK886, A potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J. Biol. Chem. 1990, 265, 1436-1442.
45. Borgeat, P.; Samuelsson, B. Metabolism of arachidonic acid in polymorphonuclear leukocytes. J. Biol. Chem. 1979, 254, 7865-7869.
46. Borgeat, P.; Samuelsson, B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. J. Biol. Chem. 1979, 254, 2643-2646.
47. Borgeat, P.; Samuelsson, B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc. Natl. Acad. Sci. USA 1979, 76, 3213-3217.
48. Khanapure, S. P.; Saba, G.; Powell, W. S.; Rokach, J. The design and synthesis of a 5-HETE affinity chromatography ligand for 5-hydroxyeicosanoid dehydrogenase. Tetrahedron Lett. 2000, 41, 5807-5811.
49. 4 and its ω-oxidation products. Prostaglandins 1983, 25, 29-37.
50. 4 20-hydroxylase from polymorphonuclear leukocytes. J. Biol. Chem. 1984, 259, 3082-3089.
51. Stamatiou, P.; Hamid, Q.; Taha, R.; Yu, W.; Issekutz, T. B.; Rokach, J.; Khanapure, S. P.; Powell, W. S. 5-Oxo-6,8,11,14-eicosatetraenoic acid stimulates eosinophil infiltration into the lungs of brown norway rats in an integrin-dependent manner. J. Clin. Invest. 1998, 102, 2165-2172.
52. 4 on human neutrophil migration and cytosolic calcium levels. J. Pharmacol. Exp. Ther. 1996, 276, 728-736.
53. Verhgen, J.; Bruynzeel, P. L. B.; Koedam, J. A.; Wassink, G. A.; deBoer, M.; Terpstra, G. K.; Kreukniet, J.; Veldink, G. A.; Vliegenthart, J. F. G. Specific leukotriene formation by purified human eosinophils and neutrophils. FEBS Lett. 1984, 168, 23-28.
54. 4 synthesis by purified human eosinophils induced by opsonized zymosan. FEBS Lett. 1985, 189, 350-354.
55. Bruynzeel, P. L. B.; Kok, P. T. M.; Vietor, R. J.; Verhagen, J. On the optimal conditions of LTC4 formation by human eosiniphils in vitro. Prostaglandins Leukotrienes Med. 1985, 20, 11-22.
56. Marcus, A. J.; Broekman, M. J.; Safier, L. B.; Ullman, H. L.; Islam, N.; Sherhan, C. N.; Rutherford, L. E.; Korchak, H. M.; Weissmann, G. Formation of leukotrienes and other hydroxy acids during platelet-neutrophil interactions in vitro. Biochim. Biophys. Res. Commun. 1982, 109, 130.
57. 4 by human platelets. Biochem. Biophys. Acta 1986, 68, 877.
58. 4. J. Biol. Chem. 1988, 263, 174-181.
59. 4 to cysteinyl-containing leukotrienes by human platelets. Eur. J. Biochem. 1988, 178, 81.
60. Khanapure, S. P.; Powell, W. S.; Rokach, J. The total synthesis of 5-Oxo-12-(S)-hydroxy-6(E),8(Z),10(E),14(Z)-eicostetraenoic acid and its 8,9-trans-isomer and their identification in human platelets. J. Org. Chem. 1998, 63, 8976-8982.
61. Powell, W. S.; Gravel, S.; Khanapure, S. P.; Rokach, J. Biological inactivation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human platelets. Blood 1999, 93, 1086-1096.
62. Chiang, N.; Arita, M.; Serhan, C. N. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukotriene Essential Fatty Acids 2005, 73, 163-177.
63. Romano, M. Lipoxin analogs and lipoxin formation in vivo. Prostaglandins Leukotriene and Essential Fatty Acids 2005, 73, 239-243.
64. Serhan, C. N.; Hamberg, M.; Samuelsson, B. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 1984, 81, 5335.
65. Serhan, C. N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997, 53, 107-137.
66. Serhan, C. N. Lipoxins and aspirin-triggered 15-epi-lipoxins: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediators 2002, 433-455.
67. DeWitt, D. L.; El-Harith, E. A.; Kraemer, S. A.; Andrews, M. J.; Yao, E. F.; Armstrong, R. L.; Smith, W. L. The aspirin heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 1990, 265, 5192-5198.
68. Lecomte, M.; Laneuville, O.; Ji, C.; DeWitt, D. L.; Smith, W. L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 1994, 269, 13207-13215.
69. Xiao, G.; Tsai, A.-L.; Palmer, G.; Boyar, W. C.; Marshall, P. J.; Kulmacz, R. J. Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2. Biochemistry 1997, 36, 1836-1845.
70. Wallace, J. L.; Devchand, P. R. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br. J. Pharmacol. 2005, 145, 275-282.
71. 4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin. Sci. 1989, 77, 195.
72. 4: Structure-function relationships. Biochem. Biophys. Res. Commun. 1991, 180, 1416.
73. 4 increases gastric resistance to aspirin-induced damage. Gastroenterology 2002, 123, 1598-1606.
74. Coleman, R. A.; Kennedy, I.; Humphery, P. P. A.; Bunce, K.; Lumley, P. Prostanoids and their receptors. Oxford, UK: Pergamon, 1990: 643-714.
75. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 1999, 79, 1193-1226.
76. 2 receptor from human blood platelets. J. Biol. Chem. 1989, 264, 16496-16501.
77. 2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle. Circulation 1985, 72, 1202-1207.
78. 2 receptor. Biochim. Biophys. Acta 1989, 1012, 184-190.
79. 2 receptors: evidence for different subclasses in the rat. Biochem. Pharmacol. 1991, 42, 537-544.
80. Sugimoto, Y.; Narumita, S.; Ichikawa, A. Insight into prostanoid functions: lessons from receptor-knockout mice. In: Curtis-Prior P.; editor. The Eicosanoids. London: John Wiely & Sons, 2004:219-225.
81. Larsson, C.; Weber, P.; Anggard, E. Arachidonic acid increases and indomethacin decreases plasma renin activity in the rabbit. Eur. J. Pharmacol. 1978, 28, 391-394.
82. 2 biosynthesis in the ureter obstructed isolated perfused kidney of the rabbit. J. Pharmacol. Exp. Ther. 1978, 205, 1-8.
83. Hudson, M.; Richard, H.; Pilote, L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. Br. Med. J. 2005, 330, 1-6.
84. Dahlen, S.-E.; Bjork, J.; Hedqvist, P.; Arfors, K. E.; Hammarstrom, S.; Lindgren, J. A.; Samuelsson, B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relavance to the acute inflammatory response. Proc. Natl. Acad. Sci. USA 1981, 78, 3887-3891.
85. 4. An inflammatory mediator in vivo. Prostaglandins 1981, 22, 213-222.
86. 4 A stereospecific stimulator for release of lysosomal enzymes from neutrophils. FEBS Lett. 1981, 130, 14-17.
87. Rae, S. A.; Smith, M. J. H. The stimulation of lysosomal enzyme secretion from human polymorphonuclear leukocytes by leukotriene B. J. Pharmacokinetics Pharmacol. 1981, 33, 616-618.
88. Votta, B.; Mong, S. Transition of affinity states for leukotriene B4 receptor in sheep lung membranes. J. Pharmacol. Exp. Ther. 1990, 265, 841-847.
89. 4 receptor: comparision to its human orthologue. Eur. J. Pharmacol. 1999, 380, 203-213.
90. 4 receptors. Prostaglandins Other Lipid Mediators 2002, 68-69, 575-585.
91. 4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl. Acad. Sci. USA 2005, 102, 17501-17506.
92. Birke, F. W.; Meade, C. J.; Anderskewitz, R.; Speck, G. A.; Jennewein, H. M. In vitro and in vivo pharmacological characterization of Biil 284, a novel and potent leukotriene B(4) receptor antagonist. J. Pharmacol. Exp. Ther. 2001, 297, 458-466.
93. Evans, J. F. Cysteinyl Leukotriene Receptors. Prostaglandins Other Lipid Mediators 2002, 68-69, 587-597.
94. Walch, L.; Norel, X.; Back, M.; Gascard, J.-P.; Dablen, S.-E.; Brink C. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br. J. Pharmacol. 2002, 137, 1339-1345.
95. Ohshima, N.; Nagase, H.; Koshino, T.; Miyamasu, M.; Yamaguchi, M.; Hirai, K.; Yamamoto, K.; Fujisawa, T.; Nakagawa, N.; Kishikawa, K.; Morita, Y. A functional study on cysLT(1) receptors in human eosinophils. Int. Arch. Allergy Appl. Immunol. 2002, 129, 67-75.
96. Mellor, E. A.; Maekawa, A.; Austen, K. F.; Boyce, J. A. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc. Natl. Acad. Sci. USA 2001, 98, 9764-9769.
97. Labat, C.; Ortiz, J. L.; Norel, X.; Gorenne, I.; Verley, J.; Abram, T. S.; Cuthbert, N. J.; Tudhope, S. R.; Norman, P.; Gardiner, P.; Brink, C. A second cysteinyl leukotriene receptor in human lung. J. Pharmacol. Exp. Ther. 1992, 263, 800-805.
98. Tudhope, S. R.; Curthbert, N. J.; Abram, T. S.; Jenning, M. A.; Maxey, R. J.; Thompson, A. M.; Norman, P.; Gardiner, P. J. Bay, u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur. J. Pharmacol. 1994, 264, 317-323.
99. Heise, C. E.; O'Dowd, B. F.; Figueroa, D. J.; Sawyer, N.; Nguyen, T.; Im, D.-S.; Stocco, R.; Bellefeuille, J. N.; Abramovitz, M.; Cheng, R.; Williams, Jr. D. L.; Zeng, Z.; Liu, Q.; Ma, L.; Clements, M. K.; Coulombe, N.; Liu, Y.; Austin, C. P.; George, S. R.; O'Neill, G. P.; Metters, K. M.; Lynch, K. R.; Evans, J. F. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 2000, 275, 30531-30536.
100. Nothacker, H.-P.; Wang, Z.; Zhu, Y.; Reinscheid, R. K.; Lin, S. H. S.; Civelli, O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol. Pharmacol. 2000, 58, 1601-1608.
101. Kamohara, M.; Takasaki, J.; Matsumoto, M.; Matsumoto, S.-I.; Saito, T.; Soga, T.; Matsushime, H.; Furuichi, K. Functional characterization of cysteinyl leukotriene CysLT2 receptor on human coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 2001, 287, 1088-1092.
102. Hui, Y.; Yang, G.; Galczenski, H.; Figueroa, D. J.; Austin, C. P.; Copeland, N. G.; Gilbert, D. J.; Jenkins, N. A.; Funk, C. D. The murine cysteinyl leukotriene 2 (CysLT2) receptor cDNA and genomic cloning, alternative splicing, and in vitro characterization. J. Biol. Chem. 2001, 276, 47489-47495.
103. Ogasawara, H.; Ishii, S.; Yokomizo, T.; Kakinuma, T.; Komine, M.; Tamaki, K.; Shimizu, T.; Izumi, T. Characterization of mouse cysteinyl leikotriene receptors mcysLT1 and mcysLT2; differential pharmacological properties and tissue distribution. J. Biol. Chem. 2002, 277, 18763-18768.
104. Sakata, K.; Back, M. Receptor preferences of cysteinyl-leukotrienes in the guinea pig lung parenchyma. Eur. J. Pharmacol. 2002, 436, 119-126.
105. Brink, C.; Dahlen, S.-E.; Drazen, J.; Evans, J. F.; Hay, D. W. P.; Rovati, G. E.; Serhan, C. N.; Shimizu, T.; Yokomizo, T. international union of pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol. Rev. 2004, 56, 149-156.
106. Vane, J. R. Inhibition of prostaglandin biosynthesis as a mechanism of action for aspirn-like drugs. Nature 1971, 231, 232-235.
107. Kean, W. F.; Buchanan, W. W. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 2005, 13, 343-370.
108. Janero, D. R.; Garvey, D. G. Nitric oxide donors as anti-platelet agents for thromboembolic disorders: clinical status and therapeutic prognosis. In: Wang P. G.; Chi T. B.; Taniguchi N.; editors. Nitric Oxide Donors. Weinheim: Wiley-VCH Press, 2005:299-328.
109. Gawaz, M.; Langer, H.; May, A. E. Platelets in inflammation and atherogenesis. J. Clin. Invest 2005, 115, 3378-3384.
110. Patrono, C.; Coller, B.; Dalen, J. E.; FitzGerald, G. A.; Gents, M.; Hirsh, J.; Roth, G. Platelet-active drugs; the relationships among dose, effectiveness, and side effects, Sixth ACCP Consensus Conference on Antithrombotic Therapy, 2001. Vol. 119. CHEST.
111. vanGijn, J.; Algra A. Aspirin and stroke prevention. Thromb. Res. 2003, 110, 349-353.
112. Taylor, D. W.; Barnet, H. J. M.; Hynes, R. B.; Freguson, G.F.; Sackett, D.L.; Thorpe, K.E.; Simard, D.; Silver, F.L.; Hachinski, V.; Clagett, G.P.; Barnes, R.; Spence, J.D. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999, 353, 2179-2184.
113. Alberts, M. J.; Bergman, D. L.; Molner, E.; Jovanovic, B. D.; Ushiwata, I.; Teruya, J. Antiplatelet effect of aspirin inpatients with cerebrovascular disease. Stroke 2004, 35, 175-178.
114. Patrono, C.; Garcia-Rodriguez L. A.; Landolfi R.; Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 2005, 353, 2373-2383.
115. Eikelboom, J. W.; Hankey, G. J. Failure of aspirin to prevent athrothrombosis: Potential mechanism and implications for clinical practise. Am J Cardiovasc Drugs 2004, 4, 57-67.
116. Fisher, M. Results of the managements of atherothrombosis with clopidogrel in high-risk patients trial: Implications for the neurologist. Arch. Neurol. 2006, 63, 20-24.
117. Babu, K. S.; Salvi, S. S. Aspirin and asthma. Chest 2000, 118, 1470-1476.
118. DeGaetano, G.; Cerletti, C.; Dejana, E.; Latini, R. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985, 72, 1185-1193.
119. MacDonald, T. M.; Wei, L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361, 573-574.
120. Farkouh, M. E.; Kirshner, H.; Harrington, R. A.; Roland, S.; Verheugt, F. W. A.; Schnitzer, T. J.; Burmester, G. R.; Mysler, E.; Hochberg, M. C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Gimona, A.; Matchaba, P.; Hawkey, C. J.; Chesebro, J. H. Comparison of lumiraxoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364, 675-84, see figure 3.
121. 2. Nature (London) 1985, 315, 511-513.
122. Hall, R. A.; Gillard, J.; Guindon, Y.; Letts, G.; Champion, E.; Ethier, D.; Evans, J.; Ford-Hutchinson, A. W.; Fortin, R.; Jones, T. R.; Lord, A.; Morton, H.; Rokach, J.; Yoakim, C. Pharmacology of L-655,240 (3-[1-(4-Chlorobenzyl)-5-fluoro-3-methylindol-2-yl]- 2,2-dimethyl-propanoic acid); a potent, selective thromboxane/ prostaglandin endoperoxide antagonist. Eur. J. Pharmacol. 1987, 135, 193-201.
123. Ford-Hutchinson, A. W.; Girad, Y.; Lord, A.; Jones, T. R.; Cirino, M.; Evans, J. F.; Gillard, J.; Hamel, P.; Leveille, C.; Masson, P.; Young, R. The pharmacology of L-670,596, a potent and selective thromboxane/ prostaglandin endoperoxide receptor antagonist Can. J. Physiol. Pharmacol. 1989, 67, 989-993.
124. Ogletree, M. L.; O'Keefe, E. H.; Durham, S. K.; Rubin, B.; Aberg, G. Gastroprotective effects of thromboxane receptor antagonists. J. Pharmacol. Exp. Ther. 1992, 263, 374-380.
125. 2/prostaglandin endoperoxide receptor antagonist J. Pharmacol. Exp. Ther. 1993, 264, 570-578.
126. Ventavis NDA accepted for priority review. DailyDrugNews.com (Daily essential), 2004.
127. FDA approves Ventavis for the treatment of pulmonary arterial hypertension (PAH). CoTherix press release 2004, Dec 29.
128. Davies, P.; Bailey, P. J.; Goldenberg, M. M.; Ford-Huchinson, A. W. The role of arachidonic acid oxygenation products in pain and inflammation. Annu. Rev. Immunol. 1984, 2, 335-357.
129. Murata, T.; Ushikubi, F.; Matsuoka, T.; Hirata, M.; Yamasaki, A.; Sugimoto, Y.; Ichikawa, A.; Abe, Y.; Tanaka, T.; Yoshida, N.; Ueno, A.; Oh-ishi, S.; Narumiya, S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388, 678-682.
130. Yaksh, T. L.; Mantyh, P. W.; Svensson, C. I. Prostanoids in pain. In: Curtis-Prior C.; editor. The Eicosanoids. London: John Wiely & Sons, Ltd, 2004:473-480.
131. Bley, K. R.; Hunter, J. C.; Eglen, R. M.; Smith, J. A. M. The role of IP prostanoid receptors in inflammatory pain. Trends Pharmacol. Sci. 1998, 19, 141-147.
132. 2 blocks inflammation, hyperalgesia and interleukin 6 production in vivo. J. Exp. Med. 1996, 184, 883-891.
133. Zhang, J.; Rivest, S. Arachidonic acid metabolites in the neurophysiological system: the fever pathway. In: Curtius-Prio P.; editor. The Eicosanoids. London: John Wiely & Sons, Ltd, 2004:461-472.
134. Zampronio, A. R.; Souza, G. E. P.; Silva, A. A.; Cunha, F. Q.; Ferreira, S. H. Interleukin-8 induces fever by a prostaglandin-independent mechanism. Am. J. Physiol. 1994, 266, R1670-R1674.
135. 2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 1990, 265, 16737-16740.
136. Masferrer, J. L.; Zweifel, B. S.; Seibert, K.; Raz, A.; Needleman, P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 1990, 86, 1375-1379.
137. Herschman, H. R. Prostaglandin synthase 2. Biochim. Biophysic. Acta 1996, 1299(1), 125-140.
138. Herschman, H. R. Function and regulation of prostaglandin synthase 2. Adv. Exp. Med. Biol. 1999, 469, 3-8.
139. Mitchell, J. A.; Akarasereenont, P.; Thiemermann, C.; Flower, R. J.; Vane, J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl. Acad. Sci. USA 1994, 90, 11693-11697.
140. Laneuville, O.; Breuer, D. K.; DeWitt, D. L.; Hla, T.; Funk, C. D.; Smith, W. L. Differential inhibition of human prostaglandin endoperoxide-H synthases-1 and -2 by nonsteroidal antiinflammatory drugs. J. Pharmacol. Exp. Ther. 1994, 271, 927-934.
141. Dannhardt, G.; Laufer, S. Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? Curr. Med. Chem. 2000, 7, 1101-1112.
142. Ryn, J. V.; Trummlitz, G.; Pairet, M. COX-2 selectivity and inflammatory processes. Curr. Med. Chem. 2000, 7, 1145-1161.
143. Patrono, C. Measurement of cyclooxygenase isozyme inhibition in humans: Exploring the clinical relevance of biochemical selectivity. Rheumatology 2001, 19, S45-S50.
144. Patrono, C.; Patrignani, P.; Rodriguez, L. A. G. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 2001, 108, 7-13.
145. Turini, M. E.; DuBois, R. N. Cyclooxygenase-2: A therapeutic target. Annu. Rev. Med. 2002, 53, 35-57.
146. deLeval, X.; Delarge, J.; Somers, F.; deTullio, P.; Henrotin, Y.; Pirotte, B.; Dogne, J.-M. Recent advances in inducible cyclooxygenase (COX-2) inhibition. Curr. Med. Chem. 2000, 7, 1041-1062.
147. Kalgutkar, A. S.; Zhao, Z. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Curr. Drug Targets 2001, 79-106.
148. Rodrigues, C. R.; Veloso, M. P.; Verli, H.; Fraga, C. A.; Miranda, A. L.; Barreiro, E. J. Selective PGHS-2 inhibitors: A rational approach for the treatment of the inflammation. Curr. Med. Chem. 2002, 9, 849-867.
149. Gans, K. R.; Galbraith, W.; Romans, R. J.; Haber, S. B.; Kerr, J. S.; Schmidt, W. K.; Smith, C.; Hewes, W. E.; Ackerman, N. R. Antiinflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. 1990, 254, 180-187.
150. Galbraith, R. DuP 697 as an agent which may be a selective cyclooxygenase inhibitor, Winter Prostaglandin Conference, Keystone, CO, USA, 1992.
151. Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, I.; Higuchi, S.; Iizuka, H.; Otomo, S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 1993, 24, 105-110.
152. Futaki, N.; Takahashi, S.; Yokoyama, M.; Arai, I.; Higuchi, S.; Otomo, S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H Synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47, 55-59.
153. Copeland, R. A.; Williams, J. M.; Giannaras, J.; Numberg, S.; Covington, M.; Pinto, D. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA 1994, 91, 11202-6.
154. Marnett, L. J.; Rowlinson, S. W.; Goodwin, D. C.; Kalgutkar, A. S.; Lanzo, C. A. Arachidonic acid oxygenation by COX-1 and COX-2; mechanisms of catalysis and inhibition. J. Biol. Chem. 1999, 274, 22903-22906.
155. Kiefer, J. R.; Pawlitz, J. L.; Moreland, K. T.; Stegeman, R. A.; Hood, W. F.; Gierse, J. K.; Stevens, A. M.; Goodwin, D. C.; Rowlinson, S. W.; Marnett, L. J.; Stallings, W. C.; Kurumbail, R. G. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000, 405, 97-101.
156. 2 synthase-1. Nature 1994, 367, 243-249.
157. Kurumbali, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by inflammatory agents. Nature 1996, 384, 644-648.
158. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K,; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
159. Ochi, T.; Goto, T. Anti-inflammatory effect of FR140423, a novel slective cyclooxygenase-2 inhibitor, in rat adjuvant arthritis without gastrointestinal side effects. J. Pharmacokinetics Pharmacol. 2000, 52, 553-560.
160. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromilish, W.; Ethier, D.; Evans, J. F.; Ford-Rutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, {MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
161. Black, W. C.; Brideau, C.; Chan, C.; Charleson, S.; Chauret, N.; Claveau, D.; Ethier, D.; Gordon, R.; Greig, G.; Guay, J.; Hughes, G.; Jolicoeur, P.; Leblanc, Y.; Nicoll-Griffith, D.; Quimet, N.; Riendeau, D.; Visco, D.; Wang, Z.; Xu L.; Prasit, P. 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. J. Med. Chem. 1999, 42, 1274-1281.
162. Khanna, I. K.; Weier, R. M.; Xiang, Y. Y.; Xu, D.; Koszyk, F. J.; Collins, P. W.; Koboldt, C. M.; Veenhuizen, A. W.; Perkins, W. E.; Casler, J. J.; Masferrer, J. L.; Zhang, Y. Y.; Gregory, S. A.; Seibert, K.; Isakson, P. C. 1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. J. Med. Chem. 1997, 40, 1634-1647.
163. Khanna, I. K,; Huff, Y. Y. R. M.; Weier, R. M.; Xu, X.; Koszyk, F. J.; Collins, P. W.; Cogburn, J. N.; Isakson, P. C.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Yuan, J.; Yang, D.; Zhang, Y. Y. Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents. J. Med. Chem. 2000, 43, 3168-3185.
164. Talley, J. A.; Brown, D. L.; Carter, J. S.; Masferrer, M. J.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
165. Khanna, I. K.; Weier, R. M.; Yu, Y.; Collins, P. W.; Miyashiro, J. M.; Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. C. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J. Med. Chem. 1997, 40, 1619-1633.
166. Matsushita, M.; Masaki, M.; Yagi, Y.; Tanaka, T.; Wakitani, K. Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats. Inflamm. Res. 1997, 46, 461-466.
167. Puig, C.; Crespo, M. I.; Godessart, N.; Feixas, J.; Ibarzo, J.; Jimenez, J.; Soca, L.; Cardelus, I.; Heredia, A.; Miralpeix, M.; Puig, J.; Beleta, J.; Huerta, J. M.; Lopez, M.; Segarra, V.; Ryder, H.; Palacios, J. M. Synthesis and biological evaluation of 3,4-Diaryloxazolones: a new class of orally active cyclooxygenase-2 inhibitors. J. Med. Chem. 2000, 43, 214-223.
168. Davies, I. W.; Marcoux, J.-F.; Corley, E. G.; Journet, M.; Cai, D.-W.; Palucki, M.; Wu, J.; Larsen, R. D.; Rossen, K.; Pye, P. J.; DiMichele, L.; Dormer, P.; Reider, P. J. A Practical synthesis of a COX-2 specific Inhibitor. J. Org. Chem. 2000, 65, 8415-8420.
169. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; DubAc, D.; Ethier, D.; Falgueyret, J. P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, J.; Mancini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girad, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C. C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
170. Khanapure, S. P.; Garvey, D. S.; Young, D. V.; Ezawa, M.; Earl, R. A.; Gaston, R. D.; Fang, X.; Murty, M.; Martino, A.; Shumway, M.; Trocha, M.; Marek, P.; Tam, S. W.; Janero, D. R.; Letts, L. G. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. J. Med. Chem. 2003, 46, 5484-5504.
171. Khanapure, S. P.; Augustyniak, M. E.; Earl, R. A.; Garvey, D. S.; Letts, L. G.; Martino, A. M.; Murty, M. G.; Schwalb, D. J.; Shumway, M. J.; Trocha, A. M.; Young, D. V.; Zemtseva, I. S.; Janero, D. R. 3-{4-(Methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: Synthesis and biological evaluation. J. Med. Chem. 2005, 48, 3930-3934.
172. Li, C.-S.; Black, W. C.; Chan, C.-C.; Ford-Hutchinson, A. W.; Gauthier, J.-Y.; Gordon, R.; Guay, D.; Kargman, S.; Lau, C. K.; Mancini, J.; Quimet, N.; Roy, P.; Vickers, P.; Wong, E.; Young, R. N.; Prasit, P. Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives. J. Med. Chem. 1995, 38, 4897-4905.
173. Kalgutkar, A. S.; Marnett, A. B.; Crews, B. C.; Remmel, R. P.; Marnett, L. J. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2000, 43, 2860-2870.
174. Bayly, C. I.; Black, W. C.; Leger, S.; Ouimet, N.; Ouellet, M.; Percival, M. D. Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg. Med. Chem. Lett. 1999, 9, 307-312.
175. COX-189: R & D Focus. Drugupdates 2002.
176. Schnitzer, T. J.; Burmester, G. R.; Mysler, E.; Hochberg, M. C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Matchaba, P.; Gimona, A.; Hawkey, C. J. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364, 665-674.
177. Chan, C.-C.; Bouce, S.; Brideau, C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.; Ford-Hutchinson, A. W.; Fprrest, M. J.; Gauthier, J. Y.; Gordon, R.; Gresser, M.; Guay, J.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'neill, G. P.; Ouellet, M.; Patrick, D.; Percival, M. D.; Perrier, H.; Prasit, P.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Visco, D.; Wang, Z.; Webb, J.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Riendeau, D. Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 1999, 290, 551-560.
178. Jackson, L. M.; Hawkey, C. J. Gastrointestinal effects of COX-2 inhibitors. Exp. Opin. Invest. Drugs 199, 8, 963-971.
179. FitzGerald, G. A.; Patrono, C. The Coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
180. Schneider, A.; Stahl, R. A. K. Cyclooxygenase-2 and the kidney: current status and potential perspectives. Nephrol Dial Transplant 1998, 13, 10-12.
181. McAdam, B. F.; Catella-Lawson, F.; Mardini, I. A.; Kapoor, S.; Lawson, J. A.; FitzGerald, G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 1999, 96, 272-277.
182. Mukherjee, D.; Nissen, S. E.; Topol, E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286, 954-959.
183. Merck & Co I. Merck announces voluntary withdrawal of Vioxx. http://www.merck.com/newsroom/pressreleases/product/20040930.html.
184. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. Adenomatous polyp prevention of vioxx (APPROVe) trial. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352, 1092-1102.
185. Furberg, C. D.; Psaty, B. M.; FitzGerald, G. A. Paracoxib, Valdecoxib, and cardiovascular risk. Circulation 2005, 111, 249-.
186. Soloman, S. D.; McMurray, J. J.; Pfeffer, M. A.; Whites, J.; Fowler, R.; Finn, P.; Zauber, W. F.; Hawk, E.; Bertagnolli, M. Adenoma prevention with ceelcoxib (APC) study investigators. Cardiovas-cular risk associated widi celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352, 1071-1080.
187. Nussmeier, N. A.; Whelton, A. A.; Brown, M. T.; Langford, R. M.; Hoeft, A.; Parlow, J. L.; Boyce, S. W.; Verburg, K. M. Complications of the COX-2 inihbitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 2005, 352, 1081-1089.
188. FDA. http://www.fda.gov/cedr/drug/infopage/cox2/default.html, 2005.
189. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006, 116, 4-15.
190. Janero, D. R.; Augustyniak, M.; Bandarage, R.; Bandarage, U.; Cochran, E.; Earl, R.; Fang, F.; Garvey, D. S.; Gaston, R.; Khanapure, S.; Letts, L. G.; Marek, P.; Martino, A.; Murty, M.; Stevenson, C.; Schroeder, J.; Shumway, M.; Tam, S. W.; Trocha, M.; Wey, S.-J.; Young, D. V. Nitrated cyclooxygenase-2 (COX-2) selective inhibitors: potentially improved cardiovascular risk profile. Proc. Soc. Exp. Biol. Med. Washington, D. C.; 2002, Abstracts # 1.
191. Ranatunge, R. R.; Augustyniak, M.; Bandarage, U. K.; Earl, R. A.; Garvey, D. S.; Janero, D. R.; Letts, L. G.; Martino, A. M.; Murty, M. G.; Richardson, S. K.; Schroeder, J. D.; Shumway, M. J.; Tam, S. W.; Trocha, A. M.; Young, D. V. Synthesis and selective cyclooxy-genase-2 (COX-2) inhibitory activity of a series of novel nitric oxide donor containing pyrazoles. J. Med. Chem. 2004, 47, 2180-2193.
192. Dhawan, V.; Schwalb, D. J.; Shumway, M. J.; Warren, M. C.; Wexler, R. S.; Zemtseva, I. S.; Zifcak, B. M.; Janero, D. R. Selctive nitros(yl)ation induced in vivo by a nitric oxide-donating cyclooxygenase-2 inhibitor: a NObonomic analysis. Free Radic. Biol. Med. 2005, 39, 1191-1207.
193. Hawkey, C. J. COX-2 chronology. Gut 2005, 54, 1509-1514.
194. 4. J. Pharmacol. Exp. Ther. 1986, 237, 558-562.
195. 4 on isolated human airway smooth muscle. Can. J. Physiol. Pharmacol. 1982, 60, 638-643.
196. Ellis, J. L.; Undem, B. J. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am. J. Respir. Crit. Care Med. 1994, 149, 118-122.
197. Misson, J.; Clark, W.; Kendall, M. J. Therapeutic advances: Leukotriene antagonists for the treatment of asthma. J. Clin. Pharm. Ther. 1999, 24, 17-24.
198. Bernard, G. R.; Korley, V.; Che, P.; Swindell, B.; Ford-Hutchinson, A. W.; Tagari, P. Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1991, 144, 263-267.
199. Sampson, A. P.; Spencer, D. A.; Green, C. P.; Piper, P. J.; Price, J. F. Leukotrienes in the sputum and urine of cystic fibrosis children. Br. J. Clin. Pharmacol. 1990, 30, 861-869.
200. Powell, W. S.; Ahmed, S.; Gravel, S.; Rokach, J. Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis. J. Allergy Clin. Immunol. 2001, 107, 272-278.
201. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1994, 86, 453-460.
202. 4-like material by cultured human keratinocytes. J. Invest. Dermatol. 1982, 78, 328.
203. 4 in psoriatic skin lesions. Prostaglandins 1985, 29, 611-619.
204. 4 stimulate dna synthesis in cultured human epidermal keratinocytes. Br. J. Dermatol. 1985, 113, 43-52.
205. Woollard, P. M. Stereochemical difference between 12-hydroxy-5,8,10,14-eicosatetraenoic acid in platelets and psoriatic lesions. Biochem. Biophys. Res. Commun. 1986, 136, 169-176.
206. Fretland, D. J.; Djuric, S. W. 12(R)- and 12(S)-hydroxyeicosatetraenoic acids: Chemistry, biology and pharmacology. Prostaglandins Leukotriene Essential Fatty Acids 1989, 38, 215-228.
207. Wang, S. S.; Rokach, J.; Powell, W. S.; Dekle, C.; Feinmark, S. J. Synthesis of 12-KETE and its 8,9-trans-isomer. Tetrahedron Lett. 1994, 35, 4051-4054.
208. Khanapure, S. P.; Shi, X. X.; Powell, W. S.; Rokach, J. Total Synthesis of a potent proinflammatory 5-oxo-ETE and its 6,7-dihydro biotransformation product J. Org. Chem. 1998, 63, 337-342.
209. Lefer, A. M. Leukotrienes as mediators of ischemia and shock. Biochem. Pharmacol. 1986, 35, 123-127.
210. Hand, J. M.; Will, J. A.; Buckner, C. K. Effects of leukotrienes on isolated guinea pig pulmonary arteries. Eur. J. Pharmacol. 1981, 76, 439-442.
211. 4 and E in guinea-pig and rat in vitro. Adv. Prostaglandin, Thromboxane Leukotriene Res. 1983, 11, 391-396.
212. 4: Effects on human and guinea-pig cardiac preparations in vitro. J. Pharmacol. Exp. Ther. 1982, 221, 235-241.
213. Woodman, O. L.; Dusting, G. J. Coronary vasoconstriction induced by leukotrines in the anaesthetized dog. Eur. J. Pharmacol. 1982, 86, 125-128.
214. 4 on guinea-pig isolated heart. J. Physiol. 1981, 317, 94P.
215. 4 on guinea-pig isolated hearts. Br. J. Pharmacol. 1982, 76, 169-176.
216. 4 in the pulmonary and coronary circulation in vitro. Br. J. Pharmacol. 1981, Proceedings Suppl. 75, 5P.
217. Takase, B.; Maruyama, T.; Kurita, A.; Uehata, A.; Nishioka, T.; Mizuno, K.; Nakamura, H.; Katsura, K.; Kanda, Y. Arachidonic acid metabolites in acute myocardial infarction. Angiology 1996, 47, 649-661.
218. Ardaillou, R. Synthesis and effects of leukotrienes and other lipoxygenase products of arachidonic acid in the kidney. Eur. J. Pharmacol. 1990, 183, 142.
219. 4 hydrolase in renal tissue of nephrotic syndrome patients. Clin. Exp. Immunol. 1999, 116, 347-353.
220. Spurney, R. F.; Klotman, P. E.; Coffman, T. M. Leukotriene (LT) production by rejecting Rat kidney allografts correlates with renal dysfunction. Clin. Res. 1990, 38, 23A.
221. Anderson, C. B.; Mangino, M. J. Arachidonate 5-lipoxygenase inhibition and acute renal allograft rejection. Transplantation Proc. 1991.
222. 4 receptor antagonist ONO-4057 inhibits nephrotoxic serum nephritis in WKY rats. J. Am. Soc. Nephrol. 1999, 10, 264-270.
223. 4 receptor antagonist ONO-4057 inhiits mesangioproliferative changes in anti-Thy-1 nephritis. Nephrol. Dial. Transplant. 2005, 20, 2697-2703.
224. 4 in acute renal ischemic-reperfusion injury. Proc. Natl. Acad. Sci. USA 2000, 97, 823-828.
225. Bernstrom, K.; Hammarstrom, S. Metabolism of leukotriene D by porcine kidney. J. Biol. Chem. 1981, 256, 9579-9582.
226. Lianos, E. A. Eicosanoids and the modulation of glomerular immune injury. Kid. Int. 1986, 29, 339.
227. Weinstein, G. D.; Ross, P.; McCullough, J. L.; Cotton, A. In: Wright N. A.; Camplejohn R. S.; editors. Psoriasis: Cell proliferation. London: Churchill Livingstone, 1983.
228. Augstein, J.; Farmer, J. B.; Lee, T. B.; Sheard, P.; Tattersall, M. L. Selective inhibitor of slow reacting substance of anaphylaxis. synthesis of a series of chromone-2-carboxylic acids. Nature (London), New Biol 1973, 245, 215-217.
229. Bhattacherjee, P.; Hammond, B.; Salmon, J. A.; Eakins, K. E. Effect of lipoxygenase products on leukocyte accumulation in the rabbit eye. Adv. Prostaglandin, Thromboxane Leukot. Res. 1982, 9, 325-330.
230. Stjernschantz, J.; Sherk, T.; Borgeat, P.; Sears, M. Intraocular effects of lipoxygenase pathway products in arachidonic acid metabolism. Acta Ophthalmol. 1984, 62, 104-111.
231. 4 on conjunctival vasopermeability and blood-aqueous barrierintegrity. Invest. Ophthalmol. Vis. Sci. 1985, 26, 481-485.
232. Davis, K. L.; Dunn, M. W.; Schwartzman, M. L. Hormonal stimulation of 12(R)-HETE, a cytochrome P450 arachidonic acid metabolite in the rabbit cornea. Current Eye Res. 1990, 9, 661-667.
233. Nishimura, M.; Schwartzman, M. L.; Falck, J. R.; Lumin, S.; Zirrolli, J. A.; Murphy, R. C. Metabolism of 12(R)-hydroxy-5,8,10,14-eicosatetraenoic acid 12(R)-HETE) in corneal tissues: Formation of novel metabolites. Arch. Biochem. Biophys. 1991, 290, 326-335.
234. Dubois, A. The role of prostaglandins and leukotrienes in the physiology and pathology of the digestive tract. Prostaglandins & Other Lipid Mediators 2000, Special Issue: Guest Editor, A. Dubois, 1-174.
235. Gyomber, E.; Vattay, P.; Szabo, S.; Rainsford, K. D. Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J. Gastroenterol. Hepatol. 1996, 11, 922-927.
236. Wallace, J. L. Lipid mediators of inflammation in gastric ulcer. Am. J. Physiol. 1990, 258, G1-11.
237. Rainsford, K. D. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal anti-inflammatory drugs in mice. Agents Actions 1987, 21, 316-319.
238. Rogers, C.; Pihan, G.; Raza, A.; Szabo, S. Possible participation of leukotrienes in the pathogenesis of gastric micosal lesions and vascular injury induced by ethanol, hcl, naoh, or aspirin in the rat. effects of the eicosapentaenoic acid or a lipoxygenase inhibitor, L-651,392. Gastroenterology 1987, 92, 1808-1817.
239. Lashner, B. A. Clinical features, laboratory findings, and course of Crohn's disease. In: Kirsner, J. B.; Shorter, R. G.; editors. Inflammatory bowel disease. Baltimore: Williams and Williams, 1995:344-354.
240. Eberhart, C. E.; Dubois, R. N. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995, 109, 285-301.
241. Wallace, J. L.; Keenan, C. M. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am. J. Physiol. 1990, 258, G527-G534.
242. Allgayer, H.; Stenson, W. F. A comparision of effects of sulfasalazine and its metabolites on the metabolism of endo-genous vs. exogenous arachidonic acid. Immunopharmacology 1988, 15, 39-46.
243. Brooks, C. D. W.; Stewart, A. O.; Basha, A.; Bhatia, P.; Rayajcek, J. D.; Martin, J. H.; Craig, R. A.; Kolasa, T.; Bouska, J. B.; Lanni, C.; Harris, R. R.; Malo, P. E.; Carter, G. W.; Bell, R. L. (R)-(+)-N-[5-(4-Fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl] -N-hydroxyurea (ABT-761), a second generation 5-lipoxygenase inhibitor. J. Med. Chem. 1995, 38, 4768-4775.
244. Bell, R. L.; Harris, R. R.; Malo, P. E.; Bouska, J. B.; Shaughnessy, T. K.; Hulkower, K. I.; Brooks, C. D. W.; Carter, G. W. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J. Pharmacol. Exp. Ther. 1997, 280, 1366-1373.
245. Martel-Pelletier, J.; Lajeunesse, D.; Reboul, P.; Pelletier, J.-P. Therapeutic role of dual inhibitors of 5-LOX and COX selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2003, 62, 501-509.
246. Charlier, C.; Henichart, J.-P.; Durant, F.; Wouters, J. Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target based approach. J. Med. Chem. 2006, 49, 186-195.
247. Laufer, S. A.; Augustin, J.; Dannhardt, G.; Kiefer, W. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J. Med. Chem. 1994, 37, 1894-1898.
248. Song, Y.; Connor, D. T.; Sercel, A. D.; Sorenson, R. J.; Doubleday, R.; Unangst, P. C.; Roth, B. D.; Beylin, V. G.; Gilbertsen, R. B.; Chan, K.; Schrier, D. J.; Guglietta, A.; Bornemeier, D. A.; Dyer, R. D. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series. J. Med. Chem. 1999, 42, 1161-1169.
249. Song, Y.; Connor, D. T.; Doubleday, R.; Sorensen, R. J.; Sercel, A. D.; Unangst, P. C.; Roth, B. D.; Gilbertsen, R. B.; Chan, K.; Schrier, D. J.; Guglietta, A.; Bornemeier, D. A.; Dyer, R. D. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J. Med. Chem. 1999, 42, 1151-1160.
250. Giannaras, A.; Selig, W.; Ellis, J.; Hullinger, T. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur. J. Pharmacol. 2005, 506, 265-271.
251. Cai, X.; Arrington, M.; Bayless, L.; Eckman, J.; Eckert, M.; Ene, D.; Ellis, J.; Hussoin, S.; Latham, M.; Lewis, T.; Libertine, L.; Nicolas, J. M.; Scannell, R.; Selig, W.; Schwartz, E.; Wels, B.; Wypij, D.; Young, M.; Zou, D. Discovery of UCB 35440: A potent orally active dual acting 5-lipoxygenase inhibitor and H1 receptor antagonist, 224th National Meeting of the American Chemical Society, Division of Medicinal Chemistry, Boston, 2002, August 14-22.
252. Muller-Peddinghaus, R.; Kohlsdorfer, C.; Theisen-Popp, P.; Fruchtmann, R.; Perzborn, E.; Beckermann, B.; Buhner, K.; Ahr, H. J.; Mohrs, K. H. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Ther. 1993, 267, 51-57.
253. Fleisch, J. H.; Cloud, M. L; Marshall, W. S. A brief review of preclinical and clinical studies with LY 171883 and some comments on newer cysteinyl leukotriene receptor antagonists. Ann. NY Acad. Sci. 1985, 524, 356-368.
254. Thornber, C. W. Isosterism and molecular modification in drug design. Chem. Soc. Rev. 1979, 563-580.
255. 4 antagonist in non-asthmatic subjects. Thorax 1987, 42, 723.
256. Krell, R. D.; Giles, R. E.; Yee, Y. K.; Snyder, D. W. In vivo pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J. Pharmacol. Exp. Ther. 1987, 243, 557-564.
257. Adkins, J. C.; Brogden, R. N. Zafirlukast, A review of its pharmacology and therapeutic potential in the management of asthma. Drugs 1998, 1998, 55.
258. 4 receptor antagonist devoid of peroximal enzyme induction. Bioorg. Med. Chem. Lett. 1995, 5, 283-288.
259. 4 receptor and antagonist. Can. J. Physiol. Pharmacol. 1995, 73, 191-201.
260. Nabe, T.; Kohno, S.; Tanpo, T.; Saeki, Y.; Yamamura, H.; Horiba, M.; Ohata, K. Inhibitory effect of ONO-1078 on specific binding of peptido leukotrienes to human lung crude membrane. Prostaglandins Leukot. Essent. Fatty Acids 1994, 51, 163-171.
261. Cole, A. T.; Hawkey, C. J. New treatments in inflammatory bowel disease. Br. J. Hosp. Med. 1992, 47, 581-590.
262. 4 receptor antagonist, in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63, 170-176.
263. Israel, E.; Cohn, J.; Dube, L.; Drazen, J. M. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996, 275, 931-936.
264. Reid, J. J. ABT-761. Curr. Opin. Investig. Drugs 2001, 2, 68-71.
265. Merck & Co. Singulair, manufacturer's prescribing information, whitehouse station, NJ.; 1999.
266. Noonan, M. J.; Chervinsky, P.; Brandon, M.; Zhang, J.; Kundu, S.; McBurney, J.; Reiss, T.F. Montelukast a potent leukotriene receptor antagonist, causes dose related improvements in chronic asthma. Eur. Respir. J. 1998, 11, 1232-1239.
267. Altman, L. C.; Munk, Z.; Seltzer, J.; Noonan, N.; Shingo, S.; Zhang, J.; Reiss, T. F. A Placebo-controlled, doseranging study of montelukast, a once-daily leukotirene receptor antagonist. J. Allergy Clin. Immunol. 1998, 102, 50-56.
268. Bisgaars, H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001, 107, 381-390.
269. Biernacki, S. A.; Kharitonov, S. A.; Biernacka, H. M.; Barnes, P. J. Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients. Chest 2005, 128, 1958-1963.
270. Tomari, S.; Shimoda, T.; Kawano, T.; Mitsuta, K.; Obase, Y.; Fukushima, C.; Matsue, H.; Kohno, S. Effects of pranlukast, a systeinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann. Allergy Asthma Immunol. 2001, 87, 156-161.
271. Yoshida, S.; Sakamoto, H.; Ishizaki, Y.; Onuma, K.; Shoji, T.; Nakagawa, H.; Hasegawa, H.; Nakabayashi, M.; Amayasu, H. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin. Exp. Allergy 2000, 30, 64-70.
272. Kobayashi, H.; Takahashi, Y.; Mitsufuji, H.; Hataishi, R.; Cui, T.; Tanaka, N.; Kawakami, T.; Tomita, T. Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast. Jap. J. Physiol. 1999, 49, 541-544.
273. Keam S. J.; Lyseng-Williamson K. A.; Goa K. L. Pranlukast: a review of its use in the management of asthma. Drugs 2003, 63, 991-1019.
274. Ravasi S.; Capra V.; Panigalli T.; Rovati G. E.; Nicosia S. Pharmacological differences among CysLT (1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem. Pharmacol. 2002, 63, 1537-1546.
275. Moreland L. W.; Cohen S. B.; Baumgartner S. W.; Tindall E. A.; Bulpitt K.; Martin R.; Weinblatt M.; Taborn J.; Weaver A.; Burge D. J.; Schiff M. H. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 2001, 28, 1238-1244.
276. Rutgeers P.; D'Haens G.; Targan, S.; Vasiliauskas E.; Hanauer S. B.; Present D. H.; Mayer L.; Van-Hogezand R. A.; Braakman T.; Dewoody K. L.; Schaible T. F.; Van-Deventer S. J. H. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Chron's disease. Gastroenterology 1999, 117, 761-769.
277. Newton R. C.; Decicco C. P. Therapeutic potential and strategies for inhibiting tumor necrosis factor-α. J. Med. Chem. 1999, 42, 2295-2314.
278. Yazdani C.; McLaughlin T.; Cummins G.; Doyle J. Comparision of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. Am. J. Manag. Care 2001, 7, 419-426.
279. Arend W. P.; Dayer J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis. Rheum. 1990, 33, 305-315.
280. Lee J. C.; Laydon J. T.; McDonnell P. C.; Gallagher T. F.; Kumar S.; Green D.; McNulty D.; Blumenthal M. J.; Heys J. R.; Landvatter S. W.; Strickler J. E.; Mclaughlin M. M.; Siemens I. R.; Fisher S. M.; Livi G. P.; White J. R.; Adams J. L.; Young P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 736.
281. Lee M. R.; Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha. protein. Curr. Med. Chem. 2005, 12, 2979-2984.
282. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 2004, 4, 372-377.
283. Dominguez C.; Powers D. A.; Tamayo N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr. Opin. Drug Disc. Development 2005, 8, 421-430.
284. Lee J. C.; Kassis S.; Kumar S.; Badger A.; Adams J. L. p38 mitogen activated protein kinase inhibitors -mechanism and therapeutic potentials. Pharmacol. Ther. 1999, 82, 389-397.
285. Lee J. C.; Laydon J. T.; McDonnell P. C.; Gallagher T. F.; Kumar S.; Green D.; McNulty D.; Blumenthal M. J.; Heys J. R.; Landvatter S. W. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
286. Blanque R.; Cottereaux C.; Gardner C. R. Effects of SK&F 86002 on cytokine-stimulated production in cultured neonatal mouse calvaria and SaOS2 osteoblastic cells: the role of prostaglandins and other mechanisms of action. Drugs Exp. Clin. Res. 1997, 23, 63-70.
287. Regan J.; Breitfelder S.; Cirillo P.; Gilmore T.; Graham A. G.; Hickey E.; Klaus B.; Madwed J.; Moriak M.; Moss N.; Pargellis C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical-candidate. J. Med. Chem. 2002, 45, 2994-2008.
288. Natarajan S. R.; Doherty J. B. P38 MAP Kinase inhibitors: Evolution of imidazole-based and Pyrido-pyrimidin-2-one lead Classes. Curr. Top. Med. Chem. 2005, 5, 987-1003.
289. Liverton N. J.; Butcher K. W.; Claiborne C. F.; Claremon D. A.; Libby B. E.; Nguyen K. T.; Pitzenberger S. M.; Selnick H. G.; Smith G. R.; Tebben A.; Vacca J. P.; Varga S. L.; Agarwal L.; Dancheck K.; Forsyth A. J.; Fletcher D. S.; Frantz B.; Hanlon W. A.; Harper C. F.; Hofsess S. J.; Kosture M.; Lin J.; Luell S.; O'Nieill E. A.; Orevillo C. J.; Pang M.; Parsons J.; Rolando A.; Sahly Y.; Visco D. M.; O'Keefe S. J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 1999, 42, 2180-2190.
290. McKenna J. M.; Halley F.; Souness J. E.; McLay I. M.; Pickett S. D.; Collis A. J.; Page K.; Ahmed I. An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors. J. Med. Chem. 2002, 45, 2173-2184.
291. Manning G.; Whyte D. B.; Martinez R.; Hunter T.; Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
292. Nikas S. N.; Drosos A. A. SCIO-469 Scios INC. Curr Opin Investig Drugs 2004, 5, 1205-1212.
293. Mavunkel B. J.; Chakrarvarty S.; Perumattan J. J.; Dugar S.; Lu Q.; Liang X. Indole derivatives as inhibitors of p38 kinase. WO-00071535: SCIOS INC, 2000.
294. Mavunkel B.; Chakravarty S.; Perumattam J.; Liu D.; Luedtke G.; Qing L.; Dugar S.; Laney M.; Henson M.; Xu Y.-J.; Schreiner G. Discovery and biological evaluation of p38a MAP kinase inhibitor SX-011, International symposium on advances in synthetic, combinatorial and medicinal chemistry" Moscow, Russia, 2004.
295. Fitzgerald C. E.; Patel S. B.; Becker J. W.; Cameron P. M.; Zaller D.; Pikounis V. B.; O'Keee S. J.; Scapin G. Structural basis for p38α MAP kinase quinazoline and pyridol-pyrimidine inhibitor specificity. Nature Struct. Biol. 2003, 10, 764-769.
296. Vertex Pharmaceuticals Inc.; Press Release (2004) October 18. http://www.vrtx.com/Pressreleases2004/Pr101804.html Preliminary phase Ila data for VX-702 demonstrates tolerability and reduction in C-reactive protein in cardiovascular patients.
297. Vertex Pharmaceuticals Inc.; Press Release (2005) June 10. http://www.vrtx.com/Pressreleases2005/Pr061005.html Vertex pharmaceuticals initiates phase Il clinicla study in rheumatoid arthritis with investigational oral p38 MAP kinase inhibitor VX-702.
298. Lowe G. D. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J. Thromb. Haemost. 2005, 3, 1618-1627.
299. Woolard K. J. Soluble bio-markers in vascular disease: much more than gauges of disease? Clin. Exp. Pharmacol. Physiol. 2005, 32, 233-240.
300. Hume D. A.; Fairlie D. P. Therapeutic targets in inflammatory disease. Curr. Med. Chem. 2005, 12, 2925-2929.
301. Pischon, T.; Hankinson, S. E.; Hotamisligil, G. S.; Rifai, N.; Willett, W. C.; Rimm, E. B. Habitual dietary intake of n-3 and n-6 fatty acids in
302. Zhao, G.; Etherton, T. D.; Martin, K. R.; West, S. G.; Gillies, P. J.; Kris-Etherton, P. M. Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J. Nutr. 2004, 134, 2991-2997.
303. Lands, W. E. M. Biochemical and cellular actions of membrane lipids. FASEB J. 1992, 6, 2530-2536.
304. Lands, W. E. M. Dietary fat and health: The evidence and the politics of prevention. Ann. N. Y. Acad. Sci. 2005, 1055, 179-192.
305. Stamp, L. K.; James, M. J.; Cleland, L. G. Diet and rheumatoid arthritis: A review of the literature. Semin. Arthritis Rheum. 2005, 35, 77-94.
306. Grimminger, F.; Mayer, K.; Kiss, L.; Walmarth, D.; Seeger, W. PAF-induced synthesis of tetraenoic and pentaenoic leukotrienes in the isolated rabbit lung. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 278, L-268-75.
307. Wallace, J. L.; McKnight, G. W. Comparison of the damage-promoting effects of leukotrienes derived from eicosapentaenoic acid and arachidonic acid on the rat stomach, J. Exp. Med. 1990, 171, 1827-1832.
308. Simopoulos, A. P. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr. 1991, 54, 438-463.
309. Simopoulos, A. P. The importance of the ratio of omega6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002, 56, 365-379.
310. Seaman, D. R. The diet-induced proinflammatory state: A cause of chronic pain and other degenerative diseases. J. Manipulative Physiol. 2002, 25, 168-179.
311. Engler, M. M.; Engler, N. M. B. Omega-3 fatty Acids: role in cardiovascular health and disease. J. Cardiovasc. Nurs. 2006, 21, 17-24.
312. Nielsen, A. A.; Jorgensen, L. G.; Nielsen, J. N.; Eivindson, M.; Gronbaek, H.; Vind, I.; Hougaard, D. M.; Skogstrand, K.; Jensen, S.; Munkholm, P.; Brandslund, I.; Hey, H. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment Pharmacol. Ther. 2005, 22, 1121-1128.
313. Wong, K. W. Clinical efficacy of n-3 fatty acid supplementation in patients with asthma. J. Am. Diet. Assoc. 2005, 105, 98-105.
314. Matsuyama, W.; Mitsuyama, H.; Watanabe, M.; Oanakahara, K.; Higashimoto, I.; Osame, M.; Arimura, K. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest 2005, 128, 3817-3827.
315. MacLean, C. H.; Mojica, W. A.; Newberry, S. J.; Pencharz, J.; Garland, R. H.; Tu, W.; Hilton, L. G.; Gralnek, I. M.; Rhodes, S.; Khanna, P.; Morton, S. C. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am. J. Clin. Nutr. 2005, 82, 611-619.
316. Bannings, M. The role of omega-3 fatty acids in the prevention of cardiac events. Br. J. Nurs. 2005, 14, 503-508.
317. Zamaria, N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod. Nutr. Dev. 2004, 44, 273-282.
318. Steinhubl, S. R.; Moliterno, D. J. The role of platelet in the pathogenesis of atherothrombosis. Am. J. Cardiovasc. Drugs 2005, 5, 399-408.
319. Egan, K. M.; Wang, M.; Fries, S.; Lucitt, M. B.; Zukas, A. M.; Pure, E.; Lawson, J. A.; FitzGerald, G. A. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005, 111, 334-342.
320. Folco, G.; Rossoni, G.; Buccellati, C.; Berti, F. Leukotrienes in cardiovascular diseases. Am. J. Respir. Crit. Care Med. 2000, 161, S112-S116.
321. 4 in different human tissues is attributable to distinct membrane bound biosynthetic enzymes. J. Biol. Chem. 1997, 272, 10182-10187.
322. Sala, A.; Folco, G. Breakthroughs and views. Biochem. Biophys. Res. Commun. 2001, 283, 1003-1006.
323. Michelassi, F.; Landa, L.; Hill, R. D.; Lowenstein, E.; Watkins, W. D.; Petkau, A. J.; Zapol, W. M. A potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 1982, 217, 841-843.
324. Janero, D. R. Nitric oxide (NO) related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Radic. Biol. Med. 2000, 28, 1494-1506.
325. McCall, T.; Whittle, B. J. R.; BoughtoSmith, N. K.; Moncada, S. Inhibition of FMLP-induced aggregation of rabbit neutrophils by NO. Br. J. Pharmacol. 1998, 95, 517P.
326. Herbaczynska-Cedro, K.; Lembowicz, K.; Pytel, B. NG-monomethyl-L-arginine increases platelet depositon on damaged endothelium in vivo: a scanning electron microscopy study. Thromb. Res. l991, 64, 1-9.
327. Kubes, P.; Suzuki, M.; Granger, D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA 1991, 88, 4651-4655.
328. Rossoni, G.; Sala, A.; Berti, F.; Testa, T.; Buccellati, C.; Molta, C.; Muller-Peddinghaus, R.; Maclouf, J.;.Folco, G. C. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J. Pharmacol. Exp. Ther. 1996, 276, 335-341.
329. Spanbroek, R.; Grabner, R.; Lotzer, Y.; Hildner, M.; Urbach, A.; Ruhling, K.; Moos, M. P. W.; Kaiser, B.; Cohnert, T. U.; Wahlers, T.; Zieske, A.; Plenz, G.; Robenek, H.; Salbach, P. Kuhn, H.; Radmark, O.; Samuelsson, B. Expanding expression of the 5-lipoxygenase pathwy within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 2003, 100, 1238-1243.
330. Mehrabian, M.; Allayee, H.; Wong, J.; Shih, W.; Wang, X-P.; Shaposhnik, Z.; Funk, C. D.; Lusis, A. J. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 2002, 91, 120-126.
331. Bergstrom, S.; Danielsson, H.; Klenberg, D.; Samuelsson, B. The enzymatic conversion of essential fatty acids into prostaglandins. J. Biol. Chem. 1994, 239, 4006.
332. Bergstrom, S.; Danielsson, H.; Samuelsson, B. The enzymatic formation of prostaglandin E2 from arachidonic acid. Biochim. Biophys. Acta 1964, 90, 207-210.
333. Rigas, B.; Kashfi, K. Cancer prevention: A new era beyond cyclooxygenase-2. J. Pharmacol. Expt. Ther. 2005, 314, 1-8.
334. s-axin-β-catenin signaling axis. Science 2005, 310, 1504-1510.
335. McAdam, B. F.; Mardini, I. A.; Habib, A.; Burke, A.; Lawson, J. A.; Kapoor, S.; FitzGerald, G. A. Effects of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest. 2000, 105, 1473-1482.
336. Kim, S. F.; Huri, D. A.; Snyder, S. H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310, 1966-1970.